Home » Newsletters » BioWorld Science

BioWorld Science

July 19, 2011

View Archived Issues

New tyrosine-protein kinase SYK inhibitors presented

New HIV-1 clade C consensus envelope sequence-based DNA vaccine is immunogenic in vivo

Novel imidazo[1,2-b]pyridazine derivative ameliorates symptoms of arthritis in vivo

New dipeptidyl peptidase 1 inhibitors claimed

Sanofi discloses novel pim inhibitors for cancer

Katholieke Universiteit Leuven describes new antifungal agents

Photocure begins enrollment in new phase II Visonac study

Merck & Co.'s new frizzled SMO receptor antagonist MK-5710 has antitumor activity in vivo

New MAP kinase-activated protein kinase 2 inhibitors discovered

PET tracer [18F]-MK-3328 shows favorable uptake in brain of patients with AD

Janssen Pharmaceuticals to divest U.S. Ortho Dermatologics division

FDA approves delayed-release mesalamine tablets for maintenance of remission of ulcerative colitis

COMP recommends orphan drug status for Nektar Therapeutics' lead oncology agent in ovarian cancer

Afexa Life Sciences clear to begin study of AFX-2 in patients with chronic lymphocytic leukemia

Cyclacel and Daiichi Sankyo amend sapacitabine licensing agreement

Daiichi Sankyo launches Lixiana in Japan

Nabi Biopharmaceuticals reports on first confirmatory phase III NicVAX study

Talon Therapeutics submits NDA for Marqibo to FDA

Dificid tablets launched in U.S. for CDI-associated diarrhea

Halaven launched in Japan for inoperable/recurrent breast cancer

Merck & Co. gains European approval for Victrelis

Japanese launch of Rivastach patch for Alzheimer's type-dementia

Chugai set to launch Mircera injection syringe in Japan for treatment of renal anemia

Phase III data presented on subcutaneous Actemra versus intravenous infusion

Upsher-Smith Laboratories initiates phase III trial of USL-261

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...